Entity

With the takeover of SynCo Bio Partners B.V. in Amsterdam, the Netherlands, in 2018 Wacker Chemie AG strengthened its pharmaceutical protein business and expanded its portfolio – an important step to keep pace with the rapidly growing biologics market. Following the acquisition in April last year, the new name Wacker Biotech B.V. came into effect in November. Just like Wacker Biotech GmbH, Wacker Biotech B.V. is a full-service contract manufacturer of biopharmaceutical proteins based on microbial systems. The new Amsterdam site joins Jena and Halle as Wacker Biotech’s third state-of-the-art production site that guarantees top quality standards in accordance with GMP (good manufacturing practice).